Exidavnemab phase 2a study expanded to include MSA patients

Stockholm, May 8, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System Atrophy (MSA) patients for treatment with the alpha-synuclein antibody exidavnemab in the ongoing EXIST Phase 2a study.

The release as fetched from its publisher. bioarctic.com ↗